|本期目录/Table of Contents|

[1]印中鹏,宋令雄,王苏梦,等.血浆抗凝血酶Ⅲ和血清IL-6与降钙素原对判断克罗恩病活动性的临床价值[J].医学研究与战创伤救治(原医学研究生学报),2018,20(01):22-25.[doi:10.3969/j.issn.1672-271X.2018.01.005]
　YIN Zhong-peng,SONG Ling-xiong,WANG Su-meng,et al.Clinical value of plasma AT-Ⅲ and serum PCT, IL-6 levels and the evaluations of disease activity in Crohn′s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(01):22-25.[doi:10.3969/j.issn.1672-271X.2018.01.005]
点击复制

血浆抗凝血酶Ⅲ和血清IL-6与降钙素原对判断克罗恩病活动性的临床价值()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年01期
页码:
22-25
栏目:
出版日期:
2018-01-22

文章信息/Info

Title:
Clinical value of plasma AT-Ⅲ and serum PCT, IL-6 levels and the evaluations of disease activity in Crohn′s disease
作者:
印中鹏; 宋令雄; 王苏梦; 汪俊军; 王锋
作者单位：210002南京，南京军区南京总医院临床检验科（印中鹏、宋令雄、王苏梦、汪俊军、王锋）
Author(s):
YIN Zhong-peng;  SONG Ling-xiong;  WANG Su-meng;  WANG Jun-jun;  WANG Feng
(Department of Clinical Laboratory, Nanjing General Hospital of Nanjing Military Region, PLA,Nanjing 210002, Jiangsu, China)
关键词:
克罗恩病; 抗凝血酶Ⅲ; 白细胞介素6; 降钙素原; 诊断; 活动性
Keywords:
Crohn′s disease;  AT-Ⅲ;  IL-6;  PCT;  diagnosis;  activity
分类号:
R574.1
DOI:
10.3969/j.issn.1672-271X.2018.01.005
文献标志码:
A
摘要:
目的 分析血浆抗凝血酶Ⅲ(AT-Ⅲ)活性和血清IL-6、降钙素原(PCT)在活动期与非活动期克罗恩病患者的水平差异及相关性，探讨三者对克罗恩病活动性的临床意义。方法 回顾性分析克罗恩病患者62例临床资料，根据克罗恩病活动指数（CDAI）分为活动组（CDAI≥150分，n=32）和缓解组（CDAI＜150分，n=30)，30例健康人群为对照组，分别检测血浆AT-Ⅲ活性和血清IL-6、PCT水平，并分析其相关性。结果 克罗恩病患者血浆AT-Ⅲ活性为（70.1±15.12）%，显著低于对照组（84.5±13.2）%（P＜0.01），血清IL-6水平为73.55(26.6,113)ng/L，显著高于对照组1.2(0.5,3.1)ng/L（P＜0.01），血清PCT水平为0.64(0.15,3.37)μg/L，显著高于对照组0.03(0.02,0.06)μg/L（P＜0.01）。克罗恩病患者中，活动期患者血浆AT-Ⅲ活性为（59.45±13.24）%，显著低于缓解组（76.24±15.53）%（P＜0.01），血清IL-6水平为65.23(53.3,155.38)ng/L，显著高于缓解组29.66(20.5,59.35)ng/L（P＜0.01），血清PCT水平为8.4(2.6,19.2)μg/L，显著高于缓解组0.29(0.13,1.20)μg/L（P＜0.05）。克罗恩病患者活动组中AT-Ⅲ活性与IL-6和PCT水平均呈明显负相关（r=-0.389，r=-0.317，P＜0.01），缓解组中AT-Ⅲ活性与IL-6和PCT水平均呈明显负相关（r=-0.308，r=-0.279，P＜0.05）。结论 联合检测血浆AT-Ⅲ活性和血清IL-6、PCT水平有助于克罗恩病患者疾病活动性的判断。
Abstract:
Objective This study was undertaken to investigate the relationship between the levels of plasma AT-Ⅲ, serum IL-6, PCT and Crohn′s disease patients. The study explored their clinical significance from inflammatory cytokines and coagulation system, and evaluate the activity in Crohn′s disease.Methods The levels of AT-Ⅲ，IL-6 and PCT were tested in 62 Crohn′s disease patients which was divided into two groups. The correlation analyses were performed.Results The level of AT-Ⅲ in Crohn′s disease patients was significantly lower than the level in healthy people [(70.1±15.12)% vs (84.5±13.2)%, P＜0.01]. On the contrary, the levels of IL-6 and PCT in Crohn′s disease patients were significantly higher than the level in healthy people [73.55(26.6,113)ng/L vs 1.2(0.5,3.1)ng/L, 0.64(0.15,3.37)μg/L vs 0.03(0.02,0.06) μg/L, P＜0.01]. The level of AT-Ⅲ in the activity group was significantly lower than the level in the remission group [(59.45±13.24)% vs (76.24±15.53)%, P＜0.01], the level of IL-6 in the activity group was significantly higher than the level in the remission group [65.23(53.3, 155.38)ng/L vs 29.66(20.5, 59.35)ng/L, P＜0.01],also the level of PCT in the activity group was significantly higher than the level in the remission group[8.4(2.6, 19.2)μg/L vs 0.29(0.13, 1.20)μg/L, P＜0.05]. In Crohn′s disease patients active group, AT-III level significantly negatively correlates with IL-6 and PCT levels (r=-0.389, r=-0.317, P＜0.01). AT-III level also significantly negatively correlates with IL-6 and PCT levels (r=-0.308, r=-0.279, P＜0.05) in the remission group.Conclusion In Crohn′s disease patients, the level of AT-III is well-correlated with IL-6 and PCT. The combined detection of plasma AT-III activity and the levels of serum IL-6 and PCT can contribute to early diagnosis of Crohn’s disease and the judgement of the disease activity.

参考文献/References:

[1]黄志梅, 刘焕云. 克罗恩病患者血清生化指标的相关性研究[J]. 西南国防医药, 2013, 23(4):369-371.[2]Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients[J]. Cytokine, 2016, 77:44-49.[3]Suzuki Y, Matsui T, Ito H, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for crohn’s disease: a prospective clinical trial[J]. Inflamm Bowel Dis, 2015, 21(9):2114-2122.[4]Yan SL, Russell J, Harris NR, et al. Platelet abnormalities during colonic inflammation[J]. Inflamm Bowel Dis, 2013, 19(6):1245-1253.[5]孙辉明, 施毅. 抗凝血酶-Ⅲ抗炎机制的研究进展[J]. 国际呼吸杂志, 2011, 31(22):1746-1750.[6]潜丽俊, 刘晟, 蔡莹. 全身炎症反应综合征患儿血浆抗凝血酶Ⅲ及D-二聚体的检测及临床意义[J]. 浙江中医药大学学报, 2010, 34(2):240-241.[7]Bernstein CN,Fried M,Krabshuis JH,et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学, 2010, 15(9):548-558.[8]中华医学会消化病学分会炎症性肠病协作组. 中国炎症性肠病诊断治疗规范的共识意见[J]. 中华内科杂志, 2008, 47(1):139-145.[9]徐晓帆, 谢颖, 龚剑峰,等. 18例克罗恩病并发肠管膀胱瘘的诊疗分析[J]. 医学研究生学报, 2013, 26(12):1266-1268.[10]兰平, 何晓生. 解读2012年中国炎性肠病诊断与治疗共识意见中一些热点问题[J]. 中华胃肠外科杂志, 2013, 16(4):304-307.[11]郭利莉, 马志坤. AT-Ⅲ与全身炎症反应综合征相关性研究[J]. 医学信息, 2013(26):92-92.[12]李原, 任建安, 吴秀文,等. 克罗恩病诊断延迟的危险因素及其对预后的影响[J]. 中华消化外科杂志, 2015, 14(7):598-600.[13]Karczewski J, Sworacwynar E, Rzymski P, et al. Selected biologic markers of inflammation and activity of Crohn’s disease.[J]. Autoimmunity, 2015, 48(5):318-327.[14]刘文, 王维, 谢龙龙,等. 活动性克罗恩病肠系膜淋巴结的CT 影像学研究[J]. 实用放射学杂志, 2016, 32(4):610-613.[15]eki C, Ipek S, Aslan F, et al. P225 Evaluation of the relationship between serum ghrelin, C-reactive protein and interleukin-6 levels and disease activity in inflammatory bowel diseases[J]. J Crohns Colitis, 2014, 8(supplement_1):S156-S156.[16]Atreya R, Neurath MF.Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer[J]. Clin Rev Allergy Immunol, 2005, 28(3):187-196.[17]Nancey S, Hamzaoui N, Moussata D, et al. Serum interleukin-6, soluble interleukin-6 receptor and Crohn′s disease activity[J]. Dig Dis Sci, 2008, 53(1):242-247.[18]Owczarek D, Cibor D, Glowacki MK, et al. Inflammatory bowel disease:Epidemiology,pathology and risk factors for hypercoagulability[J]. World J Gastroenterol, 2014, 20(1):53-63.[19]Oikonomopoulou K, Ricklin D, Ward PA, et al. Interactions between coagulation and complement—their role in inflammation[J]. Semin Immunopathol, 2012, 34(1):151-165.[20]Suarezdelarica A, Maseda E, Anillo V, et al. Biomarkers (procalcitonin, c-reactive protein, and lactate) as predictors of mortality in surgical patients with complicated intra-abdominal infection[J]. Surg Infect, 2015, 16(3):346-351.[21]黄凤楼, 刁孟元, 钱海飞,等. 降钙素原及内毒素对腹腔感染脓毒症患者预后的评估[J]. 东南国防医药, 2014,16(2):147-149.

相似文献/References:

[1]薛 松,魏 磊,程 文,等.克罗恩病膀胱瘘3例报告[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):64.
[2]杨 玲.D-二聚体、纤维蛋白原及抗凝血酶Ⅲ联合检测对早期2型糖尿病肾病的诊断价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):402.[doi:10.3969/j.issn.1672-271X.2015.04.021]
　YANG Ling..The significance of detection of D-dimer, fibrinogen and antithrombin-Ⅲ in the patients with typy-2 diabetic nephropathy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(01):402.[doi:10.3969/j.issn.1672-271X.2015.04.021]
[3]王珂,徐金中,黄迎春,等.外科加速康复团队在护理克罗恩病患者中的应用与效果观察[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):311.[doi:10.3969/j.issn.1672-271X.2017.03.023]
[4]陈媛媛,赵丽综述,汪芳裕,等.上消化道克罗恩病的临床特征及诊治现状与分析[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):385.[doi:10.3969/j.issn.1672-271X.2020.04.011]
　CHEN Yuan-yuan,ZHAO Li reviewing,WANG Fang-yu,et al.Clinical characteristics, diagnosis and treatment status and analysis of Crohn’s disease with upper gastrointestinal tract phenotype[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):385.[doi:10.3969/j.issn.1672-271X.2020.04.011]
[5]奉婧,魏娟,汪芳裕.克罗恩病合并腹盆腔脓肿的内科治疗进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):54.[doi:10.3969/j.issn.1672-271X.2022.01.012]
　FENG Jing,WEI Juan,WANG Fang-yu.Progress in medical treatment of abdominal and pelvic abscess in Crohn’s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(01):54.[doi:10.3969/j.issn.1672-271X.2022.01.012]

备注/Memo

备注/Memo:
基金项目：南京军区南京总医院科研基金（2016054）
更新日期/Last Update: 2018-01-20